Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Rahl

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Immunity|April 22, 2014
Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanismsSheng Xiao, Nir Yosef, Jianfei Yang, et al.
Nature|July 22, 2014
Targeting transcription regulation in cancer with a covalent CDK7 inhibitorNicholas Kwiatkowski, Tinghu Zhang, Peter B Rahl, et al.
Cell|September 6, 2011
BET bromodomain inhibition as a therapeutic strategy to target c-MycJake E Delmore, Ghayas C Issa, Madeleine E Lemieux, et al.
Cancer Research|November 17, 2025
Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple MyelomaW Frank Lenoir, Michael R McKeown, Giulia Giorgetti, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Immunity|April 22, 2014
Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanismsSheng Xiao, Nir Yosef, Jianfei Yang, et al.
Nature|July 22, 2014
Targeting transcription regulation in cancer with a covalent CDK7 inhibitorNicholas Kwiatkowski, Tinghu Zhang, Peter B Rahl, et al.
Cell|September 6, 2011
BET bromodomain inhibition as a therapeutic strategy to target c-MycJake E Delmore, Ghayas C Issa, Madeleine E Lemieux, et al.
Cancer Research|November 17, 2025
Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple MyelomaW Frank Lenoir, Michael R McKeown, Giulia Giorgetti, et al.
Pageof 3